Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (16131)	3/1/1998 1:57:00 PM
From: WTDEC	Respond to of 32384

Alper, I do agree 95% is not accurate. I think most WS analysts use 70% to 80%. Maybe the author is reflecting European approval rates which I have no knowledge of or some worldwide rate which might include multiple county approvals for the same drug (once a drug passes muster in the US, for example, approval in other countries ought to be close to 100%). I gather the approval percentage is high because companies don't undertake the expense unless they feel approval is quite likely. Regards, wtd